Gastric Cancer Liver Metastasis Cohort of China

Study Overview
=================
Brief Summary
-----------------
This multi-institutional retrospective cohort study aimed to describe and analyze the overall clinical characteristics, therapeutic status and prognosis pattern of gastric cancer liver metastasis (GCLM) in China.

Official Title
-----------------
Retrospective Multi-institutional Cohort Study of Gastric Cancer Liver Metastasis in Real-world Data of China

Conditions
-----------------
Stomach Neoplasms, Neoplasm Metastasis

Intervention / Treatment
-----------------
* Procedure: Gastrectomy; Hepatectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Gastric cancer liver metastases cases aged over 18 years old; Primary gastric carcinoma (including different histopathological types) confirmed by biopsy or surgery (pre-, intra- or post- treatment); In hospital cases between 2020/01/01 to 2019/12/3. Exclusion Criteria: Poor compliance to treatment or lost to follow-up; Gross loss of clinical data.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Resectable group<br> | Procedure: Gastrectomy; Hepatectomy<br> <br> * Other names: Target therapy;|
| Potentially resectable group<br> | |
| Unresectable group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| 1-year overall survival | The proportion (%) of gastric cancer liver metastasis patients that survived beyond one-year follow-up period. | 2011/01/01-2020/12/31 | 
| 3-year overall survival | The proportion (%) of gastric cancer liver metastasis patients that survived beyond three-year follow-up period. | 2011/01/01-2021/12/31 | 
| 5-year overall survival | The proportion (%) of gastric cancer liver metastasis patients that survived beyond five-year follow-up period. | 2011/01/01-2021/12/31 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The incidence of gastric cancer liver metastasis cases | The rate of gastric cancer liver metastasis cases divided by all gastric cancer cases in the study period. | 2010/01/01-2019/12/31 | 
| The proportion for synchronous and metachronous liver metastases cases | The proportion (%) of synchronous or metachronous gastric cancer liver metastases cases in all gastric cancer cases | 2010/01/01-2019/12/31 | 
| The survival of patients that recieved different therapeutic methods | The proportion (%) of patients under different therapies that survived beyond specific follow-up period. | 2010/01/01-2019/12/31 | 
| The prognostic predictive value for patients with different C-GCLM classification | The proportion (%) of patients of different classification that survived beyond specific follow-up period. | 2010/01/01-2019/12/31 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prognosis, Multidisciplinary treatment, C-GCLM Classification, Gastric cancer, Liver metastasis